Antibiotic resistance is a silent pandemic, and Bacteromic is building the diagnostic shield. While most biotechs chase drug discovery, this Polish startup is tackling the bottleneck of antibiotic susceptibility testing (AST)—the critical step that determines which drug will actually kill a resistant infection. In a market dominated by slow, manual methods, Bacteromic bets on microfluidics to speed up the decision from days to hours.

"The real battle isn't just discovering new antibiotics—it's determining which one still works, fast enough to save a life."

Their revenue of $4.3M on a 55-person team signals a lean, R&D-heavy operation. This is classic deep-tech: capital-intensive, long sales cycles, but with massive potential impact. The lack of disclosed funding isn't a red flag; it often means they're bootstrapped or have non-dilutive grants, common in EU biotech. The Polish origin is key—Poland has a strong engineering talent pool and lower costs, allowing them to stretch capital further than a Silicon Valley equivalent.

• Microfluidic AST: Replaces petri dishes with lab-on-a-chip technology for rapid testing.
• B2B Focus: Revenue model targets hospitals and diagnostic labs, not direct consumers.
• Lean Operations: $4.3M revenue with 55 employees suggests high R&D efficiency.
• Direct Traffic Dominance: 59% direct traffic indicates strong brand recall among industry professionals.